Indoleamine 2,3-dioxygenase (IDO) is highly expressed in most human tumor tissues [281], and IDO activity is closely related to the regulation of cancer immune escape mechanisms and T-cell activity [282], therefore, IDO inhibitors have become small molecule drugs with therapeutic potential. This evidence concerns the gene IDO1 and cancer.